Pop Test Oncology LLC aka Palisades Therapeutics (PT) is an innovative pharmaceutical company dedicated to developing and delivering life-saving therapeutics across diverse medical fields, including CNS, virology, oncology, bio-threats, regenerative medicine, and neurodegeneration. With a unique business model, and more than a decade of experience, PT operates as a "brain trust" of over 100 scientists, physicians, clinicians, and professionals who contribute their expertise as a dedicated team united in PT’s mission to bring groundbreaking and cost-effective therapeutic solutions to the global healthcare market.

PT’s strong network of partnerships includes collaborations with leading organizations such as the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), the Department of Defense (DoD), the Veterans Administration (VA), and the National Cancer Institute (NCI). Beyond these, PT is committed to fostering a culture of global collaboration and has established strategic alliances with academic institutions, universities, and companies worldwide. These partnerships enable PT to stay at the forefront of medical innovation, share knowledge, and accelerate the development of cutting-edge therapies that improve patient outcomes.

Currently in its Seed funding stage, PT has garnered support from “Impact Investors” among family and friends. With a commitment to financial efficiency and an exceptionally low burn rate, PT maximizes the impact of each investment dollar. As the company continues to grow and expand its global partnerships, its primary objective remains clear: to advance therapeutic innovations that make a profound difference in the lives of patients around the world.